https://www.selleckchem.com/pr....oducts/Mubritinib-TA
ed over the past 15years in VQI registries. Patients undergoing IIB and EVAR demonstrated decreases in POMI rates that correspond with a reduction in CRIs and increased preoperative statin use. CEA and SIB had no significant change in POMI rates nor CRIs. The etiology of decreased POMI rate is uncertain, but increasing statin use, patient-specific factors, and patient selection for procedures may be important drivers of this improvement. Except for TEVAR, the incidence of POMI has remained unchanged or decreased over the past
Aimer
Commentaire
Partagez
